Aerie Pharma (AERI) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aerie Pharma (AERI) PT Raised to $80 at JMP Securities; 'Rhopressa Launch in Full Stride'
March 1, 2018 1:18 PM ESTJMP Securities raised its price target on Aerie Pharma (NASDAQ: AERI) to $80.00 (from $75.00) while maintaining a Market Outperform rating.
Analyst Donald Ellis said the Rhopressa launch is in full stride. AERI management is hiring 100 sale reps in 1Q18 and... More
